Trine Alma Knudsen

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen et al. · Haematologica · 2019 · 103 citations · Full text

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

Trine Alma Knudsen, Vibe Skov, Kristen E. Stevenson et al. · Blood Advances · 2021 · 58 citations · Full text

Interferon-α Vs Hydroxyurea, Genetics, Mixed-phenotype Acute Leukemia +29

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

Julia Czech, Sabrina Cordua, Barbora Weinbergerová et al. · Leukemia · 2018 · 57 citations

Transcriptional Regulation, Increased Molecular Responses, Signal Transduction +13

Physical Activity Enhances Metabolic Fitness Independently of Cardiorespiratory Fitness in Marathon Runners

Matthew J. Laye, M. Nielsen, L. Hansen et al. · Disease Markers · 2015 · 45 citations · Full text

Physical Activity, Fitness, Cardiometabolic Risk +18

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis

Stine Ulrik Mikkelsen, Lasse Kjær, Mads Emil Bjørn et al. · Cancer Medicine · 2018 · 44 citations · Full text

Immunodeficiencies, Immunology, Pathology +19